



App No.: 09/732,998
Title: Methods for Defining MYC
Inventors: Hilary A. Collier, *et al.*

Variability from Target Preparation and Scanning




Figure 1A



App No.: 09/132,998
Title: Methods for Defining MYC...
Inventors: Hilary A. Collier, *et al.*

Variability from Independent Sampling




Figure 1B

OCT 23 2002

App No.: 09/152,998
Title: Methods for Defining MYC
Inventors: Hilary A. Collier, *et al.*

MYC induced versus Control Fibroblasts





Figure 1C



App No.: 09/732,998
Title: Methods for Defining MY...
Inventors: Hilary A. Collier, *et al.*





App No.: 097732,998
Title: Methods for Defining M...
Inventors: Hilary A. Collier, *et al.*

Variability from Target Preparation and Scanning




Figure 1E



Myc induced versus control fibroblasts




Figure 1F



Figure 2B





Figure 2A






Figure 3C

C




Figure 3B




Figure 3A

A




Figure 4




Figure 5



Figure 6A

Induced Genes										
Ornithine decarboxylase 1*	X55362	5.0	5.2	7.5	2.5	3.1				
AHCY, S-adenosylhomocysteine hydrolase*	M61832	2.3	2.4	7.3	6.8	3.4				
CCND2, cyclin D2*	D13639	4.8	2.2	5.7	4.4	5.6				
ASS, argininosuccinate synthetase*	T51288	2.7	2.1	5.5	2.9	0.5				
FKBP52, 52-kDa FK506 binding protein*	T70920	14.7	4.3	5.4	2.4	4.2				
Pre-B cell enhancing factor (PBEF)	U02020	2.5	4.0	5.2	1.9	0.4				
Tumor necrosis factor receptor associated protein (TRAP1)*	R61502	4.3	4.5	5.0	2.8	2.9				
FABP5, psoriasis-associated fatty acid binding protein*	H73758	8.3	13.6	4.7	2.7	10.0				
Nucleolin*	H17434	2.4	2.7	4.5	4.0	2.2				
GOS2, lymphocyte G0/G1 switch gene 2*	M69199	7.3	4.0	4.4	6.1	1.0				
PP1F (hCyp3), peptidyl-prolyl <i>cis-trans</i> isomerase F*	H55916	3.8	3.9	4.3	3.6	0.7				
RNA polymerase II subunit (hsRPB8)	Z49199	2.8	2.4	4.0	1.4	1.3				
Fibrillarin*	T57468	3.9	4.4	3.9	3.5	2.0				
TFRC, transferrin receptor (p90, CD71)*	R23889	2.3	2.4	3.9	2.4	9.1				
CksHs2*	X54942	2.4	2.1	3.3	3.7	3.2				
SLC16A1, solute carrier family 16*	L31801	11.1	2.7	2.9	2.0	5.6				
IARS, isoleucine-tRNA synthetase*	U04953	5.9	2.1	2.9	2.6	1.3				
HLA-DRB1, major histocompatibility complex, DR beta 5	T62633	3.4	8.9	2.9	0.4	0.5				
EST highly similar to GRPE protein homolog precursor*	T51856	9.7	3.1	2.8	2.0	7.1				
GPI, glucose phosphate isomerase	R49964	3.1	2.5	2.7	1.6	0.5				
HSPD1, heat shock 60-kD protein 1 (chaperonin)	M22382	2.7	2.3	2.7	1.8	2.2				
Hepatoma-derived growth factor*	D16431	2.2	2.3	2.6	2.6	2.5				
Splicing Factor SF2	R60749	4.3	3.6	2.5	1.6	6.3				
Coup transcription factor	M37197	3.2	2.9	2.5	1.1	2.4				
RPS11, ribosomal protein S11	X60673	7.3	2.6	2.4	1.6	1.3				
EIF5A, eukaryotic translation initiation factor 5A*	M23419	3.0	2.3	2.3	2.3	4.8				
EIF4G, eukaryotic translation initiation factor 4 gamma	R39681	2.4	3.8	2.1	0.7	1.1				
Repressed genes										
p311 (neuronal protein 3.1)*	U30521	0.29	0.38	0.15	0.13	0.43				
A2m, alpha-2-macroglobulin*	T69425	0.10	0.22	0.18	0.22	0.22				
TPM1, tropomyosin alpha chain (skeletal muscle)*	Z24727	0.33	0.31	0.20	0.14	1.10				
PDGFRA, platelet-derived growth factor alpha*	H23235	0.43	0.30	0.30	0.42	1.00				
FNI1, fibronectin1*	M76378	0.48	0.39	0.30	0.35	0.53				
CTGF, connective tissue growth factor*	X78947	0.32	0.33	0.31	0.24	1.00				
COL3A1, alpha-1 type 3 collagen*	X06700	0.34	0.38	0.39	0.33	1.00				

Figure 6B

Accession Number	MYC-ER1 MYC-ER + OHT/ control + OHT	MYC-ER2 MYC-ER + OHT/ control + OHT	MYC-ER3 MYC-ER + OHT/ control + OHT	Cycloheximide MYC-ER + OHT + cx/ control + OHT + cx	HL60 O hr/24 hr
CDKN1A, cyclin-dependent kinase inhibitor 1A (p21, Cip1)*	0.24	0.48	0.41	0.33	0.04
EST moderately similar to dithiolethione-inducible gene-2	0.22	0.38	0.44	0.93	0.28

Genes are listed in order of fold induction in experiment 3. The following genes were not present on the microarrays: EIF2a, CAD, ECA-39, MrDb, telomerase, LAF-1a, HLA-A2, gadd45, C/EBP α , and iron regulatory protein 2.

*Regulated by MYC-ER in the presence of cycloheximide.

